SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950142-21-002728
Filing Date
2021-08-24
Accepted
2021-08-24 16:03:30
Documents
18
Period of Report
2021-08-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K eh210179827_8k.htm   iXBRL 8-K 40575
2 EXHIBIT 10.1 eh210179827_ex1001.htm EX-10.1 231741
3 EXHIBI 10.2 eh210179827_ex1002.htm EX-10.2 107251
4 EXHIBIT 10.3 eh210179827_ex1003.htm EX-10.3 142039
5 EXHIBIT 10.4 eh210179827_ex1004.htm EX-10.4 23130
6 EXHIBIT 99.1 eh210179827_ex9901.htm EX-99.1 11066
  Complete submission text file 0000950142-21-002728.txt   910267

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE nrxp-20210819.xsd EX-101.SCH 3767
8 XBRL DEFINITION FILE nrxp-20210819_def.xml EX-101.DEF 27735
9 XBRL LABEL FILE nrxp-20210819_lab.xml EX-101.LAB 36811
10 XBRL PRESENTATION FILE nrxp-20210819_pre.xml EX-101.PRE 26353
11 EXTRACTED XBRL INSTANCE DOCUMENT eh210179827_8k_htm.xml XML 5572
Mailing Address 1201 N. MARKET STREET SUITE 111 WILMINGTON DE 19801
Business Address 1201 N. MARKET STREET SUITE 111 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 211202239
SIC: 2834 Pharmaceutical Preparations